tgAAC#

Related by string. * * *

Related by context. All words. (Click for frequent words.) 66 CR# vcMMAE 66 INCB# [001] 65 CIMZIA TM 65 Phase 2a trial 65 CIMZIA ™ 65 Traficet EN 64 PROMACTA 64 MYDICAR ® 64 CA4P 64 OncoVEX GM CSF 64 Androxal TM 64 efalizumab 64 TACI Ig 63 Cimzia R 63 PEG SN# 63 SNT MC# 63 HuMax EGFr 63 riociguat 63 RSD# oral 63 PXD# 63 Chrysalin 63 PEG Interferon lambda 63 eltrombopag 63 DermaVir Patch 63 PROCHYMAL 63 intravenous bisphosphonates 63 ataluren 63 Dapagliflozin 63 IRX 2 63 posaconazole 62 Phenoptin 62 oral prodrug 62 HQK 62 decitabine 62 mertansine 62 nalbuphine ER 62 Triolex 62 pomalidomide 62 budesonide foam 62 LY# [003] 62 Phase IIa trial 62 YONDELIS 62 intra articular injection 62 CIMZIA TM certolizumab pegol 62 Phase 1b 62 rilonacept 62 R#/MEM # 62 Cethrin 62 GSK# [001] 62 Glufosfamide 62 Proxinium TM 62 Fibrillex TM 62 PEG PAL 62 Symadex 62 menadione 62 huC# DM4 62 phase IIa clinical 62 NP2 Enkephalin 62 MAGE A3 ASCI 62 velafermin 61 XmAb# 61 CEQ# 61 ALN TTR# 61 methylnaltrexone 61 ESBA# 61 Chemophase 61 Tracleer R 61 Golimumab 61 TELCYTA 61 teriflunomide 61 alvimopan 61 Fx #A 61 ACZ# 61 Dacogen injection 61 elotuzumab 61 #I TM# 61 HuMax CD# 61 brivaracetam 61 nitazoxanide 61 INCB# [003] 61 Hizentra 61 IDX# 61 thymalfasin 61 adalimumab 61 recurrent glioma 61 collagenase 61 Diamyd ® 61 PD LID 61 multicenter Phase II 61 preclinically 61 ZYBRESTAT fosbretabulin 61 Phase Ib 61 mapatumumab 61 PLX cells 60 VA# [002] 60 Phase 2a 60 Excellarate 60 PDX pralatrexate 60 EVIZON 60 Cimzia ® 60 urocortin 2 60 dose escalation trial 60 MultiStem 60 GGF2 60 romidepsin 60 ACTEMRA 60 phase IIb clinical 60 rFIXFc 60 IMP# 60 Phase Ib study 60 CD# monoclonal antibody 60 Vaprisol 60 Oral NKTR 60 Panzem 60 visilizumab 60 PSMA ADC 60 Omacetaxine 60 HGS# 60 AeroLEF TM 60 Ozarelix 60 HGS ETR1 60 INT# [002] 60 Azedra 60 Aurexis 60 ganetespib 60 AIR CF1 60 CCR5 mAb 60 Genz # 60 Sym# 60 Tezampanel 60 Reolysin 60 forodesine 60 tafamidis 60 Phase III Pivotal 60 DAVANAT 60 Phase 1b trial 60 cannabinor 60 bazedoxifene conjugated estrogens 60 Phase #/#a trial 60 Ostarine 60 TRIOLEX 60 Dasatinib 60 IIa trial 60 Linaclotide 60 cediranib 60 PRT# 60 TORISEL 60 Enzastaurin 60 LEUKINE 60 antitumor effects 60 alvespimycin 60 systemically administered 60 ALN RSV# 60 Phase #/#a 59 elacytarabine 59 ISIS # 59 canakinumab 59 Alinia 59 FASLODEX 59 diabetic neuropathic pain 59 STRIDE PD 59 ENBREL 59 APTIVUS 59 BCX# 59 weekly subcutaneous injections 59 mycophenolate mofetil 59 HspE7 59 FTY# 59 Methylnaltrexone 59 Phase 2b trial 59 pralatrexate 59 administered subcutaneously 59 CCX# 59 Alocrest 59 Velcade bortezomib 59 Exherin TM 59 oral rivaroxaban 59 cobiprostone 59 HCV RESPOND 2 59 Degarelix 59 Phase Ib clinical 59 Panzem R 59 ARCALYST 59 denufosol 59 vandetanib 59 eculizumab 59 active comparator 59 HuMax CD4 59 Sandostatin LAR 59 nucleoside analog 59 novel VDA molecule 59 ascending dose 59 APTIVUS r 59 post herpetic neuralgia PHN 59 ALN VSP 59 C1 INH 59 dose escalation study 59 NLX P# 59 HCD# [002] 59 Tarceva TM 59 colesevelam HCl 59 HCV SPRINT 59 Aflibercept 59 BRIM2 59 Bezielle 59 CYT# potent vascular disrupting 59 INSPIRE Trial Phase III 59 GRN#L 59 PRECiSE 59 Fodosine 59 Aptivus ® 59 TELINTRA 59 lesinurad 59 KAPIDEX 59 Factor VIIa 59 Ocrelizumab 59 PEGylated interferon beta 1a 59 dose escalation Phase 59 ibandronate 59 Phase IIB 59 Alzhemed TM 59 OMS# 59 IMA# 59 VAPRISOL 59 Afatinib 59 TransVax ™ 59 fosbretabulin 59 proteasome inhibitor 59 oral antiviral 59 GALNS 59 Elotuzumab 59 INC# 59 GAMMAGARD 59 Phase 2b study 59 Besivance 59 AEG# 59 JAK inhibitor 59 Genasense ® 59 CB2 selective receptor agonist 59 BAY #-# 59 EUFLEXXA R 59 milatuzumab 59 CTAP# Capsules 59 CYT# 59 Virulizin ® 59 sorafenib tablets 59 HuLuc# 59 teriparatide 59 romiplostim 58 valopicitabine 58 Ophena TM 58 glatiramer acetate 58 Kepivance 58 Cethromycin 58 ARIKACE 58 Teriflunomide 58 Actilon 58 OXi# 58 dose cohort 58 albinterferon alfa 2b 58 ELND# 58 ocrelizumab 58 STELARA TM 58 laquinimod 58 pharmacodynamics 58 GRNCM1 58 OncoGel 58 OHR/AVR# 58 apremilast 58 tolvaptan 58 teduglutide 58 CORT # 58 aflibercept VEGF Trap 58 otelixizumab 58 baminercept 58 NGX# 58 TYKERB 58 Tß4 58 OMP #R# 58 anakinra 58 dacetuzumab 58 cangrelor 58 CD# antibody [001] 58 evaluating tivozanib 58 oral methylnaltrexone 58 AZILECT R 58 etanercept 58 TYZEKA 58 OMP #M# 58 SPRYCEL ® 58 Phase IIb clinical trials 58 Interferon alpha 58 R# #mg BID 58 AMD# [003] 58 ALN TTR 58 mGluR5 NAM 58 Boceprevir 58 rHuPH# 58 metaglidasen 58 ATL/TV# 58 Clolar ® 58 Raptiva R 58 placebo controlled Phase 58 liprotamase 58 ularitide 58 Phase IIa clinical 58 Microplasmin 58 chemotherapy induced neutropenia 58 Fludara 58 Pegasys ® 58 ORENCIA 58 Nasulin 58 Nanobody 58 tocilizumab 58 GOUT 58 refractory gout 58 Carfilzomib 58 SRT# [003] 58 Amplimexon 58 Parkinson disease levodopa induced 58 pegloticase 58 oral FTY# 58 clinical pharmacology studies 58 Torisel 58 Imprime PGG 58 multicenter randomized placebo controlled 58 abiraterone acetate 58 INTEGRILIN 58 relapsed MM 58 Cotara 58 Tanespimycin 58 PEGASYS ® 58 Phase #b/#a trial 58 Phase 2a clinical 58 AGGRASTAT R 58 EOquin 58 obatoclax 58 HGS ETR2 58 rindopepimut 58 selective androgen receptor modulator 58 phase 2a 58 APOPTONE 58 CYC# 58 Anturol 58 parathyroid hormone PTH 58 ISENTRESS 58 postoperative ileus 58 Valortim R 58 PREOS 58 liposome injection 58 INCB# [002] 58 GRNVAC1 58 pradefovir 58 recurrent glioblastoma multiforme 58 interferon beta 58 KNS # 58 Viramidine 58 ENMD # 58 plus methotrexate 58 Virulizin R 58 HCV infected 58 Tamibarotene 58 AERAS-#/Crucell Ad# 58 nab paclitaxel 58 Plicera 58 elagolix 58 solithromycin 58 lumiliximab 58 RRMS patients 58 dyskinesia PD LID 58 vicriviroc 58 Eculizumab 58 CTA# Injection 58 TASKi2 58 relapsed multiple myeloma 58 RDEA# 58 Ophena 58 bosentan 58 confirmatory Phase III 58 PROCRIT ® 58 DAPT 58 Phase 1a clinical 58 ORENCIA R 58 lenalidomide Revlimid R 58 INGN 58 pharmacokinetic PK study 58 oral deforolimus 58 humanized anti 58 idraparinux 58 Bortezomib 58 samalizumab 58 Aryplase 58 GEM OS1 58 ADAGIO study 58 maximally tolerated dose 58 investigational monoclonal antibody 58 uric acid lowering 58 midstage clinical 58 DU #b 58 tipranavir 58 angiogenesis inhibitor 57 KOMBIGLYZE XR 57 Phase Ia 57 Adlea 57 Saforis 57 Archexin 57 RhuDex 57 Copegus ribavirin 57 depsipeptide 57 TRO# 57 PEGylated 57 Xanafide 57 PEG INTRON R 57 Phase Ib clinical trials 57 CoFactor 57 metreleptin 57 treatment naïve genotype 57 adalimumab Humira 57 daclizumab 57 EOquin TM 57 ALGRX 57 AZX# 57 inflammatory arthritis 57 neurogenic orthostatic hypotension 57 rNAPc2 57 orally administered inhibitor 57 trastuzumab Herceptin R 57 ThGRF 57 glufosfamide 57 eniluracil 57 ISTODAX 57 Empatic 57 multicenter Phase III 57 Ketotransdel 57 selective modulator 57 BoNTA 57 PRX# 57 Amigal 57 synthetic retinoid 57 NEUPOGEN 57 symptomatic BPH 57 ROTARIX 57 RAPTIVA 57 imatinib therapy 57 ADVANCE PD 57 GVAX 57 PROLASTIN C 57 FAME Study 57 TAXUS TM 57 MAXY alpha 57 ToGA 57 interferon alfa 57 CRLX# 57 ACTEMRA TM 57 NeuroVax TM 57 telaprevir VX 57 RhuDex ® 57 fenofibric acid 57 diarrhea predominant irritable 57 inhibitor RG# 57 diabetic macular edema DME 57 LT NS# 57 Aclidinium 57 relapsing MS 57 pharmacodynamic effects 57 mcg dose 57 CBLC# 57 Aplidin 57 eosinophilic asthma 57 ruxolitinib 57 Phase IIIb clinical 57 Navelbine 57 CINTREDEKIN BESUDOTOX 57 Teriparatide 57 Natalizumab 57 IMGN# 57 Phase 2b clinical 57 primary immunodeficiency PI 57 EndoTAG TM -1 57 ZOLINZA 57 USL# 57 phase IIb trial 57 docetaxel chemotherapy 57 Phase 1a 57 BioNumerik 57 TRILIPIX 57 pertuzumab 57 QUADRAMET 57 Relivar 57 SAR# [004] 57 vidofludimus 57 Ampligen ® 57 AGILECT R 57 antitumor effect 57 RAV# 57 AzaSite Plus 57 LymphoStat B 57 Aclasta 57 Lubiprostone 57 rFVIIa 57 ulimorelin 57 CERVARIX 57 LIVALO 57 Gemzar ® 57 CANCIDAS 57 torezolid phosphate 57 tramiprosate Alzhemed TM 57 MEK inhibitor 57 dosing cohort 57 Amrubicin 57 immunomodulator 57 Gabapentin GR 57 oral picoplatin 57 6R BH4 57 Betaferon ® 57 TPI ASM8 57 antiretroviral naive 57 calcitonin 57 intranasal formulation 57 nucleotide analog 57 Quinamed 57 peginterferon 57 cartilage regeneration 57 biologic therapy 57 Protelos 57 MYCAMINE 57 deacetylase inhibitors 57 AVN# [001] 57 Ilaris 57 FOLOTYN ® 57 HCV protease inhibitor 57 Valortim 57 prucalopride 57 lixisenatide 57 ImmunoVEX HSV2 57 Phase 2b Clinical Trial 57 imetelstat 57 Diabetic Macular Edema 57 desvenlafaxine succinate 57 huN# DM1 57 AQ4N 57 velaglucerase alfa 57 JANUVIA 57 Neulasta ® 57 Pegasys plus Copegus 57 ProSavin 57 PRADAXA 57 Sudhir Agrawal D.Phil 57 ruboxistaurin 57 GATTEX ® 57 MGCD# [001] 57 MAA submission 57 ORENCIA ® 57 phase IIb III 57 investigational therapies 57 Phase III Clinical Trial 57 olaparib 57 Preclinical studies 57 anticancer compound 57 TBC# 57 ACV1 57 PDE4 inhibitor 57 dose proportionality 57 ganaxolone 57 PegIntron 57 midstage trials 57 vinorelbine 57 #mg BID [001] 57 opioid induced bowel dysfunction 57 PS# [001] 57 Raptiva ® 57 Pralatrexate 57 Gliadel Wafer 57 pitavastatin 57 pegfilgrastim 57 talactoferrin 57 plasma kallikrein inhibitor 57 OncoVEX 57 Tolvaptan 57 Blinatumomab 57 ATL# [001] 57 Etanercept 57 dirucotide 57 idarubicin 56 VEGF inhibitors 56 RANK Ligand inhibitor 56 ZYBRESTAT 56 hyperphenylalaninemia HPA due 56 phase IIb 56 IPX# 56 Cimzia TM 56 refractory cutaneous T 56 febuxostat 56 EFAPROXYN 56 MGd 56 Zerenex 56 Zavesca ® 56 tesmilifene 56 Proellex TM 56 Phase IIa 56 S/GSK# 56 NVA# 56 daunorubicin 56 axitinib 56 hA# 56 dose escalation clinical 56 placebo controlled clinical 56 saline placebo 56 forodesine hydrochloride 56 peginterferon alfa 56 SinuNase 56 radiolabeled TM# 56 GAMMAGARD LIQUID 56 TG# [003] 56 relapsed refractory multiple myeloma 56 methylnaltrexone bromide 56 rilpivirine 56 Seliciclib 56 ICA # 56 TMC# [002] 56 MNTX 56 crizotinib PF # 56 retinal vein occlusion 56 CRx 56 Candesartan 56 TYGACIL 56 RSD# 56 PREZISTA r 56 PMX # 56 TNF antagonist 56 FOLPI 56 tezampanel 56 topical diclofenac 56 certolizumab pegol 56 TASKi3 56 REMICADE ® 56 Tyrima 56 immune modulatory 56 bardoxolone methyl 56 REYATAZ R 56 interferon alfa 2b 56 AZILECT ® 56 Increlex ® 56 Increlex R 56 PLX PAD 56 ABSORB trial 56 plasma pharmacokinetics 56 #D#C# 56 phase IIb study 56 oral ridaforolimus 56 mecamylamine 56 IFN beta 56 Triapine R 56 delafloxacin 56 hypercalcemia 56 ongoing Phase 1b 56 nonclinical studies 56 subcutaneously administered 56 Behcet uveitis 56 JAK inhibitors 56 Leukine 56 SEBIVO 56 Tocilizumab 56 EZN 56 hylan GF 56 bicifadine 56 sipuleucel T 56 subcutaneous SC 56 Insegia 56 tolerability 56 G CSF 56 PAOD 56 Allovectin 7 R 56 cell lymphoma CTCL 56 invasive candidiasis 56 Aplidin R 56 odanacatib 56 tapentadol ER 56 osteoarthritis OA 56 ozarelix 56 adecatumumab 56 tanespimycin 56 KRN# 56 JAK1 56 Telintra 56 neratinib 56 VPRIV 56 LEVADEX 56 orally administered 56 intravitreal injection 56 sulodexide 56 peg IFN 56 acyclovir Lauriad R 56 Debio 56 vismodegib 56 intravesical infusion therapy 56 HeFH 56 treatment naive genotype 56 ARIXTRA 56 Cannabinor 56 RG# [001] 56 INTEGRILIN R 56 Apaziquone 56 alagebrium 56 Hycamtin 56 ONTAK 56 multicenter Phase 56 GRN# 56 STELARA ™ 56 interferon gamma 1b 56 AA Amyloidosis 56 motesanib 56 CIMZIA R 56 favorable pharmacokinetic profile 56 dose cohorts 56 vorinostat 56 TLK# 56 eritoran 56 Oral Fingolimod 56 bardoxolone 56 Hepatocellular Carcinoma HCC 56 ZACTIMA 56 pharmacokinetic PK 56 ELACYT 56 urate lowering 56 eliglustat tartrate 56 CIPN 56 dexrazoxane 56 AVANDIA 56 Vicinium TM 56 Phase 1b clinical 56 PEGPH# 56 cMET 56 Vandetanib 56 Laquinimod 56 Safinamide 56 omega interferon 56 refractory multiple myeloma 56 tolevamer 56 dexpramipexole 56 TB4 56 eprotirome 56 pharmacodynamic profile 56 Naglazyme 56 Phase #b/#a 56 Navelbine ® 56 docetaxel Taxotere ® 56 ONGLYZA ™ 56 preclinical studies 56 THR beta agonist 56 IAP inhibitors 56 TMC# [001] 56 LEVAQUIN 56 Omacetaxine mepesuccinate 56 GTC recombinant human 56 Raptiva r 56 Dyloject TM 56 virus HCV protease inhibitor 56 Allovectin 7 ® 56 Solazed TM 56 LEXIVA r 56 sorafenib Nexavar 56 GnRH agonists 56 MEND CABG 56 multicenter placebo controlled 56 NUVIGIL 56 LHON 56 orally dosed 56 investigational humanized monoclonal antibody 56 Cleviprex TM clevidipine 56 G#DT 56 Ceplene/IL-2 56 ILUVIEN ® 56 Combination REOLYSIN R 56 Ventavis 56 octreotide 56 Thiovir 56 lorvotuzumab mertansine 56 ofatumumab 56 Topical Interferon Alpha 2b 56 perampanel 56 REOLYSIN ® 56 intravitreal insert 56 Pemetrexed 56 pharmacokinetic studies 56 Aurora kinase inhibitor 56 Ixempra 56 DEB# 56 strontium ranelate 56 granisetron 56 Prodarsan ® 56 telomerase therapeutic 56 LymphoStat B belimumab 56 #ME# 56 dose limiting toxicities 56 adenoviral 56 pegylated interferon alfa 2a 56 Octreolin 56 GLYX 56 bexarotene 56 QLT# 56 orally bioavailable 56 IL# PE#QQR 56 dose escalation 56 Prostate AdenoCarcinoma Treatment 56 UPLYSO 56 trastuzumab emtansine T DM1 56 ZADAXIN 56 analgesic efficacy 56 Mipomersen 56 Eltrombopag 56 SinuNase TM 56 atrasentan 56 intravenous bolus 56 RECOTHROM 56 Kamada AAT 56 PNP inhibitor 56 mu opioid receptor antagonist 56 Noxafil 56 AMEVIVE 56 AGGRASTAT ® 56 pharmacodynamic PD 56 Welchol 56 anticancer activity 56 PSN# [002] 56 MoxDuo 56 lupus nephritis 56 PI3K inhibitor 56 tasocitinib 56 antibody MAb 56 ApoB SNALP 56 NUEDEXTA 56 antisense drug 56 FFNS 56 Cloretazine R VNP#M 56 ribavirin RBV 55 systemic lupus erythematosus SLE 55 pan HDAC inhibitor 55 ankylosing spondylitis AS 55 zileuton 55 icatibant 55 insulin detemir 55 trastuzumab DM1 T DM1 55 multiple ascending dose 55 anti leukemic 55 Phase Ib II 55 Sapacitabine 55 ara C 55 PRTX 55 Targretin 55 PNT# 55 Personalized Immunotherapy 55 post menopausal osteoporosis 55 erythropoietic 55 immunogenicity 55 custirsen 55 refractory CLL 55 IMiDs 55 xanthine oxidase inhibitor 55 SCIg 55 Hsp# Inhibitor 55 Advaxis Phase 55 edoxaban 55 LE DT 55 fibrotic disease 55 VEGF Trap 55 lintuzumab SGN 55 randomized Phase IIb 55 intravenous belinostat 55 HDACi 55 bendamustine 55 IMC A# 55 MAP# 55 NATRECOR ® 55 iniparib 55 Altastaph 55 phase Ib clinical 55 PREOS R 55 FOLFOX6 55 superficial bladder cancer 55 intra articular injections 55 Capesaris 55 Tavocept 55 candesartan cilexetil 55 placebo controlled 55 lomitapide 55 TNF alpha inhibitor 55 tegaserod 55 TAXUS Stent 55 PROSTVAC TM 55 rALLy clinical trial 55 JAK2 inhibitor 55 TMC# C# 55 TAXOTERE R 55 FOSRENOL ® 55 telaprevir dosing 55 subcutaneous formulation 55 null responder HCV 55 docetaxel Taxotere R 55 COPAXONE R 55 ZOSTAVAX 55 Novolimus 55 XIAFLEX 55 Adalimumab 55 Phase IIb trial 55 MLN# 55 RNAi therapeutic targeting 55 alicaforsen enema 55 ancrod 55 lenalidomide dexamethasone 55 Neovascular AMD 55 ciclesonide 55 prasterone 55 IMPACT DCM 55 MGCD# [002] 55 erlotinib Tarceva ® 55 R sorafenib tablets 55 phase Ib 55 CCX# B 55 MEK inhibitors 55 etanercept Enbrel 55 TEMODAL 55 ritonavir boosted 55 R roscovitine 55 Tovaxin 55 NEUMUNE 55 trodusquemine 55 Taxotere ® 55 fallopian tube cancers 55 golimumab 55 vinorelbine tartrate 55 BrachySil TM 55 STELARA 55 ILLUMINATE 55 linaclotide 55 COMFORT II 55 pivotal bioequivalence 55 Tarvacin 55 sunitinib malate 55 Filgrastim 55 Vitaxin 55 Mylotarg 55 Homspera 55 EXPAREL ™ 55 AVE# 55 rapid virologic response 55 GLP toxicology studies 55 DexaSite 55 Tasimelteon 55 leukemia AML 55 insulin degludec 55 Dupuytren Contracture 55 immunomodulatory 55 8mg/kg 55 clinical trials Multikine 55 Asentar 55 volociximab 55 Pirfenidone 55 PrevOnco ™ 55 ANAVEX #-# [001] 55 registrational trial 55 #mg doses [002] 55 IL #E 55 trastuzumab Herceptin 55 SUTENT 55 atazanavir ritonavir 55 standard chemotherapy regimen 55 ustekinumab 55 CGEN # 55 Engerix B 55 seliciclib 55 Phase IIIb study 55 metformin sulfonylurea 55 CCR5 antagonist 55 ORMD 55 stage IIIB 55 Xcytrin 55 nilotinib 55 cancer neuroendocrine tumor 55 IBS C 55 mg kg dose 55 placebo controlled clinical trials 55 MyVax R 55 painful diabetic neuropathy 55 hepatitis C HCV 55 CINOD 55 dacetuzumab SGN 55 Zolinza 55 estramustine 55 occlusion PAO 55 adult chronic ITP 55 REP# 55 cilengitide 55 BiovaxID 55 pemetrexed Alimta 55 LibiGel ® 55 enzastaurin 55 ocular formulation 55 PRISTIQ

Back to home page